|
|
 |
|
Viewing report
|
|
|
|
HIV/AIDS Therapeutics Market to 2017 - Superior Combination Therapies and Decreasing Mortality to Sustain Market Growth Despite Major Patent Expiries
GBI Research, Oct 2011, Pages: 96
HIV/AIDS Therapeutics Market to 2017 - Superior Combination Therapies and Decreasing Mortality to Sustain Market Growth Despite Major Patent Expiries
Summary
GBI Research, the leading business intelligence provider, has released its latest research, “HIV/AIDS Therapeutics Market to 2017 - Superior Combination Therapies and Decreasing Mortality to Sustain Market Growth Despite Major Patent Expiries”. It provides in-depth analysis of the unmet needs, drivers and barriers that affect the global HIV/AIDS therapeutics market. The report analyzes the markets for HIV/AIDS in the US, the top five European countries (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage pattern and annual cost of treatment are forecast until 2017 for key geographies in the leading therapeutic segments. Furthermore, the report provides competitive benchmarking for the leading companies and analyzes the mergers and acquisitions (M&A) and licensing agreements that shape the global markets.
The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.
Scope
The scope of this report includes -
- Annualized market data for the HIV therapeutics market from 2002 to 2010, forecast until 2017.
- Analysis of the HIV therapeutics market in the leading geographies of the world: the US, the UK, Germany, France, Italy, Spain, and Japan.
- Market characterization of the HIV therapeutics market including market size, annual cost of therapy, sales volume and treatment usage patterns.
- Key drivers and barriers that have a significant impact on the market.
- Coverage of pipeline molecules in various phases of drug development.
- Competitive benchmarking of leading companies. The key companies studied in this report are Gilead Sciences Inc, GlaxoSmithKline, Bristol-Myers Squibb, Abbott Laboratories, Merck & Co and Pfizer Inc.
- Key M&A activities, licensing agreements, that have taken place between 2008 and 2009 in the global HIV therapeutics market.
Reasons to buy
The report will assist business development and marketing executives to strategize their product launches, by allowing them to -
- Align product portfolio to the markets with high growth potential.
- Develop market entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth.
- Reinforce R&D pipelines by identifying new target mechanisms which can produce first in class molecules with more efficiency and better safety.
- Develop key strategic initiatives by understanding key focus areas of leading companies.
- Exploit in-licensing and out-licensing opportunities by identifying products that could fill portfolio gaps.
|
|
|
|
